Replimune: Goldman Sachs reports 5.3% ownership stake
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 4,418,837.86 shares of Replimune Group Inc. common stock, representing 5.3% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 4,418,837.86 shares of Replimune Group Inc. common stock, representing 5.3% of the class. All voting and dispositive authority is reported as shared, with no sole voting or dispositive power.
The position is held through Goldman Sachs & Co. LLC, a broker-dealer and registered investment adviser and a subsidiary of The Goldman Sachs Group, Inc. The reporting units within Goldman Sachs disclaim beneficial ownership for certain client accounts and investment entities where third parties hold economic interests.
Key Figures
Key Terms
beneficial ownership financial
parent holding company financial
broker or dealer financial
investment adviser financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Replimune Group Inc (REPL) does Goldman Sachs report?
Which Goldman Sachs entities are reporting ownership in REPL?
What percentage of Replimune Group Inc (REPL) does Goldman Sachs’ position represent?
Does Goldman Sachs claim full beneficial ownership of its REPL holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.